Terns Pharmaceuticals, Inc. (TERN): Price and Financial Metrics
TERN Price/Volume Stats
| Current price | $4.91 | 52-week high | $14.04 |
| Prev. close | $5.03 | 52-week low | $4.38 |
| Day low | $4.79 | Volume | 641,000 |
| Day high | $5.20 | Avg. volume | 565,238 |
| 50-day MA | $5.81 | Dividend yield | N/A |
| 200-day MA | $9.10 | Market Cap | 299.86M |
TERN Stock Price Chart Interactive Chart >
Terns Pharmaceuticals, Inc. (TERN) Company Bio
Terns Pharmaceuticals, Inc. operates as a biopharmaceutical company. The Company discovers and develops molecularly-targeted and oral molecule drugs for the treatment of liver disease and cancer. Terns Pharmaceuticals serves customers worldwide.
Latest TERN News From Around the Web
Below are the latest news stories about TERNS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate TERN as an investment opportunity.
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)FOSTER CITY, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced that it has granted as of September 1, 2023 equity inducement awards to two new non-executive employees under the terms of the 2022 Employment Inducement A |
Terns Pharmaceuticals to Participate in Upcoming September Investor ConferencesFOSTER CITY, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in September. 2023 Wells Fargo Healthcare Conference |
Terns Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Updates- Terns reported positive top-line data from the Phase 2a DUET trial of TERN-501 (THR-β) in NASH, with TERN-501 meeting all primary and secondary endpoints - TERN-701 (allosteric BCR-ABL) Phase 1 clinical trial for CML on track to initiate in second half of 2023; enrollment progress from ongoing China Phase 1 clinical trial presented at 2023 ASCO Annual Meeting - TERN-601 (GLP-1) program in obesity highlighted in preclinical data presented at ADA’s 83rd Annual Scientific Meeting; on track to ini |
Terns Achieves Primary Endpoint and All Secondary Endpoints in Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASHTERN-501 demonstrated dose dependent MRI-PDFF reductions at Week 12 as a once-daily, low dose, and combinable oral therapy TERN-501 (6mg) showed statistically significant mean relative liver fat content reduction of 45% as assessed by MRI-PDFF with 64% of patients achieving >30% PDFF reduction All TERN-501 doses were well-tolerated with no gastrointestinal and no cardiovascular safety signals Company to host conference call and webcast at 4:30 pm ET today FOSTER CITY, Calif., Aug. 08, 2023 (GLOB |
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)FOSTER CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, non-alcoholic steatohepatitis (NASH) and obesity, today announced that it has granted as of August 1, 2023 an equity inducement award to one new employee under the terms of the 2022 Employment Inducement Award Plan (the “I |
TERN Price Returns
| 1-mo | -8.57% |
| 3-mo | -42.57% |
| 6-mo | -57.38% |
| 1-year | -22.68% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -51.77% |
| 2022 | 43.99% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...